1. Home
  2. TBPH vs CRTO Comparison

TBPH vs CRTO Comparison

Compare TBPH & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.52

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$17.14

Market Cap

806.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
CRTO
Founded
2013
2005
Country
United States
France
Employees
N/A
3649
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
824.9M
806.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
TBPH
CRTO
Price
$16.52
$17.14
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$18.40
$34.00
AVG Volume (30 Days)
292.0K
313.6K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
279.13
38.95
EPS
N/A
0.15
Revenue
$15,386,000.00
$2,296,692,000.00
Revenue This Year
$8.46
N/A
Revenue Next Year
N/A
$5.54
P/E Ratio
N/A
$114.07
Revenue Growth
N/A
27.65
52 Week Low
$9.10
$15.58
52 Week High
$21.03
$27.48

Technical Indicators

Market Signals
Indicator
TBPH
CRTO
Relative Strength Index (RSI) 50.10 46.78
Support Level $16.14 $16.14
Resistance Level $17.21 $20.16
Average True Range (ATR) 0.38 0.86
MACD -0.08 -0.06
Stochastic Oscillator 43.53 33.30

Price Performance

Historical Comparison
TBPH
CRTO

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.

Share on Social Networks: